Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Health Care Shares Slip as Trump Sets Rules for Coronavirus Vaccine -- Health Care Roundup

10/29/2020 | 04:31pm EST

Health-care companies slipped as Covid-19 remains in focus.

A Trump administration plan announced late Wednesday would allow seniors and people in private health-insurance plans to be among those who won't be charged for a coronavirus vaccine. Medicare will cover the cost of administering the vaccine for seniors under the plan. In addition, the administration will require all providers of Covid-19 tests to post their cash prices for the tests online.

Separately, private insurers would be required to publish the prices they have negotiated with providers under a Trump administration rule completed Thursday. Insurers and hospitals have criticized the White House initiatives as too expensive and burdensome and of little use to consumers they say are unlikely to shop around based on negotiated rates.

Meanwhile, Russian-speaking criminal hackers have targeted several U.S. hospitals in recent weeks with a type of cyberattack potentially capable of disrupting critical patient care, in an apparent coordinated campaign that security experts warned could soon target hundreds more and lead to a loss of life.

Moderna signed a new contract with Japan's government to supply 50 million doses of its Covid-19 vaccine, one of the leading coronavirus shots in development, and said it received in the latest quarter $1.1 billion of deposits from other governments that had previously signed supply deals. With the new Japan contract, Moderna has committed to supplying between 175 million and more than 610 million doses to several countries, including the U.S., Canada and Switzerland, based on what the company has publicly disclosed. It also has deals with Israel and Qatar but hasn't disclosed how many doses will be supplied.

 Write to Amy Pessetto at amy.pessetto@dowjones.com 

(END) Dow Jones Newswires

10-29-20 1730ET

All news about MODERNA, INC.
04:31aPFIZER : Preparing for COVID-19 vaccine distribution in Alberta
AQ
12/02U.S. employers could mandate a COVID-19 vaccine, but are unlikely to do so - ..
RE
12/02FDA Head Defends Covid-19 Vaccine-Approval Process
DJ
12/02Pfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 7th Update
DJ
12/02Pfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 6th Update
DJ
12/02New York Will Get Enough Doses of Covid-19 Vaccine for 170,000 People -- 2nd ..
DJ
12/02VACCINE PRIORITY LIST MUST BE REFINE : Tam
AQ
12/02PFIZER, BIONTECH'S COVID-19 VACCINE : What You Need to Know
DJ
12/02ASTRAZENECA : As coronavirus soars, U.S. cheers Britain's vaccine approval
RE
12/02Pfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 5th Update
DJ
More news
Financials (USD)
Sales 2020 449 M - -
Net income 2020 -673 M - -
Net cash 2020 2 584 M - -
P/E ratio 2020 -97,0x
Yield 2020 -
Capitalization 56 587 M 56 587 M -
EV / Sales 2020 120x
EV / Sales 2021 7,25x
Nbr of Employees 1 100
Free-Float 90,0%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 114,35 $
Last Close Price 143,00 $
Spread / Highest target 29,4%
Spread / Average Target -20,0%
Spread / Lowest Target -58,0%
EPS Revisions
Managers
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.631.08%56 587
LONZA GROUP AG56.34%45 782
CELLTRION, INC.91.71%42 101
IQVIA HOLDINGS INC.10.05%32 601
SEAGEN INC.54.94%31 921
IMMUNOMEDICS, INC.315.22%20 324